7. Lambert M Schimmelmann BG, Karow A, et al. Subjective well-being and initial dysphoric reaction under antipsychotic drugs _/ Concepts, measurement and clinical relevance. Pharmacopsychiatry 2003;/36(Suppl 3):/181-90.
8. Rogers A, Day JC, Williams B, et al. The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia. Soc Sci Med 1998;/47:/ 1313-23.
9. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002;/63:/892-909.
Contact: Louise Marland, AstraZeneca, Tel : +44-1625510782 (office) or Mobile: +44-(0)-7919-565988, Email: louise.marland@astrazeneca.com; Sarah Winkless, Hill & Knowlton, Tel: +44-(0)20-7413-3204, Mobile: +44-(0)7771-757695, Email: sarah.winkless@hillandknowlton.com ; Karine Jegard, Hill & Knowlton, Tel: +44-(0)20-7413-3052, Mobile: +44-(0)7771-596959, Email: kjegard@hillandknowlton.com
